trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,lung,4', 'lung', 'nsclc', 'destiny,lung02', 'sclc']
the #oncoalerttoptweet day4 #esmo22 #eons15 tweet: oncoalert colleague dose matters!!
destiny-lung02 trial. same efficacy, less toxicity including pneumonitis in her2 mut #nsclc with 5.4 vs 6.4 dose. should be the standard dose best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??